ARTICLE | Emerging Company Profile
Volastra raises $12M seed led by Polaris to shut down metastasis
Volastra aims to halt cancer metastasis by targeting chromosomal instability
February 12, 2020 12:34 AM UTC
Updated on Feb 14, 2020 at 8:22 PM UTC
A trio of Weill Cornell and Sloan Kettering researchers have launched Volastra with $12 million in seed funding to develop therapies targeting chromosomal instability -- a driver of cancer metastasis.
Polaris Partners led the seed round on Tuesday with participation from Droia Oncology Ventures, the Global Health Sciences Fund from Quark Venture LP and GF Securities, and Arch Venture Partners...